The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia

  title={The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia},
  author={F. Legrand and A. Renneville and E. Macintyre and S. Mastrilli and F. Ackermann and J. M. Cayuela and Philippe Rousselot and A. Schmidt-Tanguy and O. Fain and M. Michel and Jean-Pierre de Jaur{\'e}guiberry and P. Hatron and P. Cony-Makhoul and D. Lefranc and D. S{\`e}ne and V. Cottin and M. Hamidou and O. Lidove and A. Baruchel and S. Dubucquoi and O. Bl{\'e}try and C. Preudhomme and M. Capron and L. Prin and J. E. Kahn},
  pages={e1 - e9}
  • F. Legrand, A. Renneville, +22 authors J. E. Kahn
  • Published 2013
  • Medicine
  • Medicine
  • AbstractImatinib is the treatment of choice for FIP1L1/PDGFRA (F/P)-associated chronic eosinophilic leukemia (F/P+ CEL), but its optimal dosing, duration, and possibility of discontinuation are still a matter of debate. A retrospective multicenter study was conducted with 44 F/P+ CEL patients identified in the French Eosinophil Network and treated with imatinib. The most frequently involved systems were skin (57%), spleen (52%), and lung (45%), and eosinophilic heart disease was observed in 15… CONTINUE READING
    61 Citations
    Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript
    • 8
    • Highly Influenced
    Imatinib for the treatment of hypereosinophilic syndromes
    • G. Helbig
    • Medicine
    • Expert review of clinical immunology
    • 2018
    • 6
    The Lymphoid Variant of Hypereosinophilic Syndrome
    • 51
    Myeloid neoplasms with eosinophilia.
    • 97
    • PDF
    Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes
    • 9


    Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.
    • 209
    • Highly Influential
    • PDF
    Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
    • 332
    • PDF
    Cell clonality in hypereosinophilic syndrome: what pathogenetic role?
    • 27
    The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study
    • 171
    • Highly Influential
    • PDF
    Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate
    • 13
    KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.
    • 87